Abstract
The purpose of this review is to provide an up-to-date summary of the current knowledge and understanding of the molecular alterations and pathways relevant to the clinical outcome of glioblastoma patients and their potential use in designing personalized treatment for these patients. This article also discusses the potential of molecular profiling as a diagnostic modality, possible therapeutic implications of MGMT promoter methylation, the targeted inhibition of angiogenesis, and assessment of the tumor’s molecular background with respect to PI3K/AKT pathway activation and associated molecules (EGFR, EGFRvIII, PTEN).
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Department of Health and Human Services, Centers for Disease Control and Prevention (CDC), National Program of Cancer Registries (NPCR): Central Brain Tumor Registry of the United States. Available at: http://www.cbtrus.org/reports//2007-2008/2007report.pdf. Accessed June 28, 2008.
Zhang M, Chakravarti A: Novel radiation-enhancing agents in malignant gliomas. Semin Radiat Oncol 2006, 16:29–37.
Kaur B, Tan C, Brat DJ, et al.: Genetic and hypoxic regulation of angiogenesis in gliomas. J Neurooncol 2004, 70:229–243.
Mason WP, Maestro RD, Eisenstat D, et al.: Canadian recommendations for the treatment of glioblastoma multiforme. Curr Oncol 2007, 14:110–117.
Heimans JJ, Taphoorn MJ: Impact of brain tumour treatment on quality of life. J Neurol 2002, 249:955–960.
Palanichamy K, Erkkinen M, Chakravarti A: Predictive and prognostic markers in human glioblastomas. Curr Treat Options Oncol 2006, 7:490–504.
Nieder C: Treatment of newly diagnosed glioblastoma multiforme. J Clin Oncol 2002, 20:3179–3180.
Kleihues P, Ohgaki H: Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro Oncol 1999, 1:44–51.
Reardon DA, Wen PY: Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist 2006, 11:152–164.
Shirahata M, Iwao-Koizumi K, Saito S, et al.: Gene expression-based molecular diagnostic system for malignant gliomas is superior to histological diagnosis. Clin Cancer Res 2007, 13:7341–7356.
Sathornsumetee S, Rich JN, Reardon DA: Diagnosis and treatment of high-grade astrocytoma. Neurol Clin 2007, 25:1111–1139, x.
Nutt CL, Mani DR, Betensky RA, et al.: Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 2003, 63:1602–1607.
van den Bent MJ, Kros JM: Predictive and prognostic markers in neuro-oncology. J Neuropathol Exp Neurol 2007, 66:1074–1081.
Whittle IR, Short DM, Deighton RF, et al.: Proteomic analysis of gliomas. Br J Neurosurg 2007, 21:576–582.
Cairncross JG, Ueki K, Zlatescu MC, et al.: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998, 90:1473–1479.
Yip S, Iafrate AJ, Louis DN: Molecular diagnostic testing in malignant gliomas: a practical update on predictive markers. J Neuropathol Exp Neurol 2008, 67:1–15.
Louis DN, Holland EC, Cairncross JG: Glioma classification: a molecular reappraisal. Am J Pathol 2001, 159:779–786.
Watanabe K, Tachibana O, Sata K, et al.: Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996, 6:217–223.
Freije WA, Castro-Vargas FE, Fang Z, et al.: Gene expression profiling of gliomas strongly predicts survival. Cancer Res 2004, 64:6503–6510.
Chakravarti A, Noll E, Black PM, et al.: Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol 2002, 20:1063–1068.
Chakravarti A, Zhai GG, Zhang M, et al.: Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene 2004, 23:7494–7506.
Sher DJ, Henson JW, Avutu B, et al.: The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma. J Neurooncol 2008, 88:43–50.
Chakravarti A, Tyndall E, Palanichamy K, et al.: Impact of molecular profiling on clinical trial design for glioblastoma. Curr Oncol Rep 2007, 9:71–79.
Karayan-Tapon L, Quillien V, Guilhot J, et al.: Predictive value of MGMT in glioblastoma: a multicenter study [abstract]. J Clin Oncol 2008, 26(Suppl):22065.
Hegi ME, Diserens AC, Gorlia T, et al.: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997–1003.
Stupp R, Hegi ME, Gilbert MR, Chakravarti A: Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol 2007, 25:4127–4136.
Reardon D, Fink K, Nabors B, et al.: Phase IIa trial of cilengitide (EMD121974) single-agent therapy in patients (pts) with recurrent glioblastoma (GBM): EMD 121974-009 [abstract]. J Clin Oncol 2007, 25(Suppl):2000.
Omuro AM, Faivre S, Raymond E: Lessons learned in the development of targeted therapy for malignant gliomas. Mol Cancer Ther 2007, 6:1909–1919.
Reardon DA, Wen PY: Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist 2006, 11:152–164.
Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al.: Phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas. Clin Cancer Res 2007, 13:1253–1259.
Cloughesy TF, Prados MD, Wen PY, et al.: A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM) [abstract]. J Clin Oncol 2008, 26(Suppl):2010b.
de Boüard S, Herlin P, Christensen JG, et al.: Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. Neuro Oncol 2007, 9:412–423.
Batchelor TT, Sorensen AG, di Tomaso E, et al.: AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11:83–95.
de Groot JF, Gilbert MR: New molecular targets in malignant gliomas. Curr Opin Neurol 2007, 20:712–718.
Butowski NA, Lamborn K, Chang S, et al.: Phase I/II study of enzastaurin (ENZ) plus temozolomide (TMZ) and radiation therapy (XRT) in patients with glioblastoma multiforme (GBM) or gliosarcoma (GS) [abstract]. J Clin Oncol 2008, 26(Suppl):3559.
Wen PY, Yung WK, Lamborn KR, et al.: Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 2006, 12:4899–4907.
Marosi C, Vedadinejad M, Haberler C, et al.: Imatinib mesylate in the treatment of patients with recurrent high grade gliomas expressing PDGF-R [abstract]. J Clin Oncol 2006, 24(Suppl):1526.
Viola FS, Katz A, Arantes A, et al.: Phase II trial of high dose imatinib in recurrent glioblastoma multiforme (GBM) with platelet derived growth factor receptor (PDGFR) expression [abstract]. J Clin Oncol 2007, 25(Suppl):2056.
Kirkpatrick JP, Rich JN, Vredenburgh JJ, et al.: Final report: phase I trial of imatinib mesylate, hydroxyurea, and vatalanib for patients with recurrent malignant glioma (MG) [abstract]. J Clin Oncol 2008, 26(Suppl):2057.
Reardon DA, Desjardins A, Vredenburgh JJ, et al.: Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. Neuro Oncol 2008, 3:330–340.
Chaskis C, Sadones J, Michotte A, et al.: A phase II trial of sunitinib in patients with recurrent high-grade glioma [abstract]. J Clin Oncol 2008, 26(Suppl):13001.
Chakravarti A, Delaney MA, Noll E, et al.: Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas. Clin Cancer Res 2001, 7:2387–2395.
Mellinghoff IK, Wang MY, Vivanco I, et al.: Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005, 353:2012–2024.
Van den Bent MJ, A. Brandes, R. Rampling, et al.: Randomized phase II trial of erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): EORTC 26034 [abstract]. J Clin Oncol 2007, 25(Suppl):2005.
Chakravarti A, Berkey B, Robins I, et al.: An update of phase II results from RTOG 0211: a phase I/II study of gefitinib with radiotherapy in newly diagnosed glioblastoma [abstract]. J Clin Oncol 2006, 24(Suppl):1527.
Cloughesy TF, Yoshimoto K, Nghiemphu P, et al.: Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 2008, 5:e8.
Friedman HS, Desjardins A, Vredenburgh JJ, et al.: Phase II trial of erlotinib plus sirolimus for recurrent glioblastoma multiforme (GBM) [abstract]. J Clin Oncol 2008, 26(Suppl):2062.
Phuphanich S, Chamberlain M, Mikkelsen T, et al.: A phase I trial of gefitinib and sirolimus in adults with recurrent glioblastoma multiforme (GBM) [abstract]. J Clin Oncol 2008, 26(Suppl):2088.
Goudar RK: Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther 2005, 4:101–112.
Yang L, Clarke MJ, Carlson BL, et al.: PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel. Clin Cancer Res 2008, 14:3993–4001.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mladkova, N., Chakravarti, A. Molecular profiling in glioblastoma: Prelude to personalized treatment. Curr Oncol Rep 11, 53–61 (2009). https://doi.org/10.1007/s11912-009-0009-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11912-009-0009-3